These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26890978)

  • 1. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
    Wondimu A; Postma MJ; van Hulst M
    Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
    Choi W; Shim E
    Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
    Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
    MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
    Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
    MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.